专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2014210747A 細胞性免疫誘導能が改善された経口ワクチン审中-公开
标题翻译：具有改善细胞介导的免疫诱导作用的口服疫苗
公开(公告)号：JP2014210747A
公开(公告)日：2014-11-13
申请号：JP2013088800
申请日：2013-04-19
申请人：アンジェスMg株式会社 , Anges Mg Inc , バイオリーダーズコーポレーションBioleaders Corporation , Bioleaders Corp , バイオリーダーズコーポレーションBioleaders Corporation
发明人： NOMURA EIJI , TENMAN AKIKO , NAKAZAWA TAKAHIRO , MORISHITA RYUICHI
IPC分类号： A61K39/07 , A61P31/12
CPC分类号： A61K39/12 , A61K9/14 , A61K35/747 , A61K2039/521 , A61K2039/523 , A61K2039/54 , A61K2039/542 , C12N7/00 , C12N2710/20034
摘要：【課題】標的抗原を表面発現する死菌化乳酸菌を有効成分とする経口ワクチンの有効投与量を低減させる製剤技術を提供すること。【解決手段】平均粒子径2.68〜30μmの、病原体抗原を表面発現する死菌化乳酸菌又はその微粒化物を含む、当該病原体感染性疾患の予防又は治療のための経口製剤。粒子径2.68〜30μmの、標的抗原を表面発現する死菌化乳酸菌又はその微粒化物を含む、当該標的抗原に対する細胞性免疫を誘導するための経口製剤。【選択図】なし
摘要翻译：要解决的问题：提供减少含有作为活性成分的口服疫苗的有效剂量的药物技术杀死在表面上表达靶抗原的乳酸菌。解决方案：提供了用于预防或治疗病原体感染性疾病，其含有平均粒径为2.68〜30μm的表面致死性抗原的杀死的乳酸菌或其雾化物。本发明提供一种用于诱导针对所述靶抗原的细胞介导性免疫的口服制剂，其含有在粒径为2.68〜30μm的表面上表达靶抗原的杀死的乳酸菌或其雾化物。

2. 发明专利

JP2005336081A Reexpression inhibitor against nr2b-nmda receptor 审中-公开
标题翻译：抑制NR2B-NMDA受体的抑制剂
公开(公告)号：JP2005336081A
公开(公告)日：2005-12-08
申请号：JP2004155679
申请日：2004-05-26
申请人： Anges Mg Inc , National Institute Of Advanced Industrial & Technology , アンジェスMg株式会社 , 独立行政法人産業技術総合研究所
发明人： KIYOSUE KAZUYUKI , MORISHITA RYUICHI
IPC分类号： A61K48/00 , A61K31/7125 , A61P25/00 , A61P25/02 , A61P25/04 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a technique for controlling expression of an NR2B-NMDA receptor and to provide a prophylactic and therapeutic agent for pain, an inhibitor against fixation of memories related to psychic traumata and an inhibitor against neurocyte death.
SOLUTION: The reexpression inhibitor against the NR2B-NMDA receptor, the prophylactic and therapeutic agent for pain, the inhibitor against fixation of memories related to psychic trauma and the inhibitor against neurocyte death comprise an NF-κB decoy as an effective ingredient.
COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种控制NR2B-NMDA受体表达的技术，并提供一种用于疼痛的预防和治疗剂，一种抑制与心理创伤有关的记忆的抑制剂和一种抑制神经细胞死亡的抑制剂。解决方案：针对NR2B-NMDA受体的再表达抑制剂，疼痛的预防和治疗剂，与心理创伤相关记忆的固定抑制剂和针对神经细胞死亡的抑制剂的抑制剂包括NF-κB诱饵作为有效成分。版权所有（C）2006，JPO＆NCIPI

3. 发明专利

JP2004358234A Needleless syringe with a plurality of nozzle holes 审中-公开
公开(公告)号：JP2004358234A
公开(公告)日：2004-12-24
申请号：JP2004139364
申请日：2004-05-10
申请人： Anges Mg Inc , Ryuichi Morishita , Shimadzu Corp , アンジェスMg株式会社 , 株式会社島津製作所 , 竜一森下
发明人： MORISHITA RYUICHI , TOMITA NARUYA , KUNUGIZA YASUO , TANIYAMA YOSHIAKI , KOIKE HIROMI , UDAGAWA HARUHIDE , KIMURA TATSUO
IPC分类号： C12N15/09 , A61K31/7088 , A61K35/74 , A61K38/00 , A61K38/22 , A61K38/27 , A61K38/43 , A61K38/55 , A61K48/00 , A61M5/30 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/08 , A61P29/00 , A61P35/04 , A61P37/06 , A61P37/08
CPC分类号： A61M5/30 , A61M5/19
摘要： PROBLEM TO BE SOLVED: To provide a needleless syringe for jet-injecting various kinds of medical solutions from a plurality of nozzle holes to uniformly inject them into the whole treated part. SOLUTION: The needleless syringe comprises a medical solution chamber 22 for storing the medical solution L, formed with the plurality of nozzle holes 94 and provided with a plurality of pistons 93 corresponding to the plurality of nozzle holes 94 respectively, and a syringe body 12 provided with a pressing mechanism 32 for pressing the pistons 93 toward the nozzle holes 94 to inject the medical solution L from the nozzle holes 94. COPYRIGHT: (C)2005,JPO&NCIPI

4. 发明专利

JP2009142295A Cyclic dumbbell decoy oligodeoxynucleotide (cdodn) containing transcribed dna-bound site 有权
标题翻译：包含可转移的DNA结合位点的环状二聚体脱羧基寡核苷酸（CDODN）
公开(公告)号：JP2009142295A
公开(公告)日：2009-07-02
申请号：JP2009075173
申请日：2009-03-25
申请人： Anges Mg Inc , In-Kyu Lee , アンジェスMg株式会社 , イン−キュリー
发明人： LEE IN-KYU , MORISHITA RYUICHI
IPC分类号： C12N15/09 , A61K9/127 , A61K31/711 , A61K31/713 , A61K48/00 , A61P1/04 , A61P3/06 , A61P5/14 , A61P9/04 , A61P9/10 , A61P9/14 , A61P11/06 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a more efficient and more effective means for treating or preventing transcription factor-related diseases and disorders. SOLUTION: The cyclic dumbbell oligodeoxynucleotide (CDODN) having two loop structures and one stem structure is provided, wherein the stem structure contains a nucleotide sequence bindable to a DNA-bound domain of a transcription factor. A pharmaceutical composition containing the above CDODN is also provided. This pharmaceutical composition is usable for treating and/or preventing such transcription factor-related diseases or disorders. The method for using this composition comprises administering a subject with a curatively effective amount of a CDODN having two loop structures and one stem structure, wherein the stem structure contains a nucleotide sequence bindable to the transcription factor's DNA-bound domain. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供治疗或预防转录因子相关疾病和病症的更有效和更有效的手段。解决方案：提供具有两个环结构和一个茎结构的环状哑铃寡脱氧核苷酸（CDODN），其中茎结构含有与转录因子的DNA结合结构域结合的核苷酸序列。还提供了含有上述CDODN的药物组合物。该药物组合物可用于治疗和/或预防此类转录因子相关疾病或病症。使用该组合物的方法包括施用具有有效量的具有两个环结构和一个茎结构的CDODN的受试者，其中所述茎结构含有与转录因子的DNA结合结构域结合的核苷酸序列。版权所有（C）2009，JPO＆INPIT

5. 发明专利

JP2009138004A Gene transfer of angiogenic factor for skin disease 审中-公开
标题翻译：神经病因基因转移对皮肤病的影响
公开(公告)号：JP2009138004A
公开(公告)日：2009-06-25
申请号：JP2009023184
申请日：2009-02-04
申请人： Anges Mg Inc , アンジェスMg株式会社
发明人： MORISHITA RYUICHI , NAKANISHI KUNIAKI , KANEDA YASUSHI , KOTANI HITOSHI
IPC分类号： A61K48/00 , A61K9/127 , A61K38/00 , A61K38/17 , A61K38/18 , A61K38/19 , A61P17/00 , A61P17/02 , A61P17/14
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： PROBLEM TO BE SOLVED: To provide a therapeutic agent for injury including a hepatocyte growth factor (HGF) as an active ingredient.
SOLUTION: A composition including angiogenic factor genes selected from a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGF), a hypoxia inducible factor (HIF) or the like, as active ingredients, is used as a therapeutic agent or a preventing agent and is administered to affected parts of the skin disease as a target site.
COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供包含肝细胞生长因子（HGF）作为活性成分的损伤治疗剂。解决方案：包含选自肝细胞生长因子（HGF），血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF），缺氧诱导因子（HIF）等）的血管生成因子基因的组合物作为活性成分，作为治疗剂或预防剂使用，作为目标部位施用于皮肤病的影响部位。版权所有（C）2009，JPO＆INPIT

6. 发明专利

JP2008132303A Biological member 审中-公开
标题翻译：生物会员
公开(公告)号：JP2008132303A
公开(公告)日：2008-06-12
申请号：JP2007195813
申请日：2007-07-27
申请人： Anges Mg Inc , Mmt:Kk , Regenetiss Kk , アンジェスMg株式会社 , リジェンティス株式会社 , 株式会社エム・エム・ティー
发明人： MAZAKI OSAMU , SHIBA HATSUICHI , MORISHITA RYUICHI , IMURA KOICHI , AKAGAWA YASUMASA
IPC分类号： A61L27/00
CPC分类号： A61L27/02 , A61K31/43 , A61K31/436 , A61K31/663 , A61K31/704 , A61K33/24 , A61K38/14 , A61K38/1875 , A61K45/06 , A61L27/54 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a biological member used for supplementing a bone or an alveolar bone having defects due to surgery, an accident or the like which sustainingly releases a bioactive substance which acts only on osteocyte regeneration. SOLUTION: In the biological member, an osteogenetic component is absorbed by a porous body selected from hydroxyapatite, calcium phosphate, β-TCP (tricalcium phosphate [β-Ca 3 (PO 4 ) 2 ]), coral, calcium carbonate, titanium oxide, alumina, zirconia, silicon nitride and ceramics. The osteogenetic component is preferably a polyphosphoric acid or its pharmaceutically acceptable salts, a NF-κB decoy or a bone morphogenetic protein (BMP). COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：提供用于补充由于手术导致的缺陷的骨骼或牙槽骨的生物部件，维持释放仅作用于骨细胞再生的生物活性物质的事故等。解决方案：在生物成分中，成骨组分被选自羟基磷灰石，磷酸钙，β-TCP（磷酸三钙[β-Ca 3 （PO 4 ），珊瑚，碳酸钙，氧化钛，氧化铝，氧化锆，氮化硅和陶瓷。成骨组分优选为多磷酸或其药学上可接受的盐，NF-κB诱饵或骨形态发生蛋白（BMP）。版权所有（C）2008，JPO＆INPIT

7. 发明专利

JP2005306877A Pharmaceutical composition containing decoy and method for using the same 有权
标题翻译：含有DECOY的药物组合物及其使用方法
公开(公告)号：JP2005306877A
公开(公告)日：2005-11-04
申请号：JP2005128753
申请日：2005-04-26
申请人： Anges Mg Inc , アンジェスMg株式会社
发明人： MORISHITA RYUICHI , AOKI MOTOKUNI , OGIWARA TOSHIO , KANEDA YASUSHI , NAKAMURA HIROSHIGE
IPC分类号： C12N15/09 , A61K31/7088 , A61K45/00 , A61K47/10 , A61K47/44 , A61K48/00 , A61P1/04 , A61P17/00 , A61P17/02 , A61P17/06 , A61P37/08
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition developed based on suggestion that a transcription factor, including NF-κB, is concerned in various kinds of diseases through expression of many genes which are under transcriptional control thereof and capable of efficaciously treating the diseases, especially skin diseases, including atopic dermatitis, vulgar psoriasis, contact dermatitis, keloid, bedsore, ulcerative colitis, and Crohn's disease.
SOLUTION: This pharmaceutical composition is used for treating the skin diseases, wherein the composition contains at least one decoy and a pharmaceutically acceptable carrier. An NF-κB decoy, an STAT-6 decoy, an AP-1 decoy, and an Ets decoy are especially used as the decoy. Further, an oligonucleotide combining with the decoys is used as the decoy. A petroleum jelly, or the petroleum jelly containing stearyl alcohol or a liquid paraffin, is used as the carrier.
COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种基于提示包括NF-κB在内的转录因子涉及各种疾病的药物组合物，其通过表达许多在其转录控制下并能够有效治疗的基因尤其是皮肤疾病，包括特应性皮炎，牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎和克罗恩病。解决方案：该药物组合物用于治疗皮肤疾病，其中组合物含有至少一种诱饵和药学上可接受的载体。 NF-κB诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵特别用作诱饵。此外，将与诱饵组合的寡核苷酸用作诱饵。使用含油硬脂或含有硬脂醇或液体石蜡的凡士林作为载体。版权所有（C）2006，JPO＆NCIPI

8. 发明专利

JP2014060968A Dna vaccine comprising specific epitope of apolipoprotein (a) 有权
标题翻译：包含APOLIPOPROTEIN特异性抗原的DNA疫苗（A）
公开(公告)号：JP2014060968A
公开(公告)日：2014-04-10
申请号：JP2012208796
申请日：2012-09-21
申请人： Anges Mg Inc , アンジェスMg株式会社
发明人： KYUTOKU MARIKO , NAKAGAMI YOSHINORI , KORIYAMA HIROSHI , NAKAGAMI FUTOSHI , MORISHITA RYUICHI
IPC分类号： C12N15/09 , A61K35/76 , A61K39/00 , A61K39/12 , A61P9/10 , C07K14/775
CPC分类号： A61K39/0012 , A61K39/292 , A61K2039/53 , A61K2039/545 , A61K2039/575 , A61K2039/58 , C12N7/00 , C12N15/85 , C12N2730/10142 , C12N2730/10143 , C12N2730/10171
摘要： PROBLEM TO BE SOLVED: To provide a DNA vaccine capable of treating or preventing arterial sclerosis while avoiding autoreactive T cell induction.SOLUTION: The present invention provides a treating or preventing agent of arterial sclerosis, which comprises an expression vector coding chimera hepatitis B virus core antigen polypeptide with an amino acid sequence comprising a specific epitope of apolipoprotein (a) being inserted. The amino acid sequence comprising the specific epitope is inserted between amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
摘要翻译：要解决的问题：提供能够治疗或预防动脉硬化同时避免自身反应性T细胞诱导的DNA疫苗。解决方案：本发明提供动脉硬化症的治疗或预防剂，其包含编码嵌合体乙型肝炎病毒核心的表达载体具有包含载脂蛋白（a）的特异性表位的氨基酸序列的抗原多肽。包含特异性表位的氨基酸序列插入在乙型肝炎病毒核心抗原多肽的氨基酸残基80和81之间。

9. 发明专利

JP2013129648A Skin care agent containing antimicrobial active polypeptide having collagen gel contractile activity, human skin fibroblast proliferative activity and hyaluronic acid-producing activity 有权
标题翻译：含有胶原凝胶活性的抗微生物活性多肽的皮肤护理剂，人皮肤纤维蛋白原增殖活性和产酸活性活性
公开(公告)号：JP2013129648A
公开(公告)日：2013-07-04
申请号：JP2012215415
申请日：2012-09-28
申请人： Anges Mg Inc , アンジェスMg株式会社
发明人： MORISHITA RYUICHI , TOMIOKA HIDEKI , TENMAN AKIKO , TAMURA NAO , SAITO YOSHIMI
IPC分类号： A61K8/64 , A61K38/00 , A61P17/00 , A61P17/10 , A61Q19/00 , A61Q19/08
摘要： PROBLEM TO BE SOLVED: To provide a polypeptide having excellent collagen gel contractile activity, human skin fibroblast proliferative activity and hyaluronic acid-producing activity as well as antimicrobial activity, and to provide a skin care agent including the polypeptide as an active ingredient.SOLUTION: The polypeptide includes an amino-acid sequence represented by sequence No.1. According to this, an antimicrobial active polypeptide having excellent collagen gel contractile activity, human skin fibroblast proliferative activity and hyaluronic acid-producing activity is provided. Further, a skin care agent including the polypeptide as an active ingredient is provided.
摘要翻译：要解决的问题：提供具有优异的胶原蛋白凝胶收缩活性，人皮肤成纤维细胞增殖活性和透明质酸产生活性以及抗微生物活性的多肽，并提供包含多肽作为活性成分的护肤剂。解决方案：多肽包含序列号1所示的氨基酸序列。因此，提供了具有优异的胶原凝胶收缩活性，人皮肤成纤维细胞增殖活性和透明质酸生成活性的抗微生物活性多肽。此外，提供了包含多肽作为活性成分的护肤剂。

10. 发明专利

JP2012025759A Medicinal composition for angiogenic therapy 有权
标题翻译：药物治疗用药物组合物
公开(公告)号：JP2012025759A
公开(公告)日：2012-02-09
申请号：JP2011190400
申请日：2011-09-01
申请人： Anges Mg Inc , Ryuichi Morishita , アンジェスMg株式会社 , 竜一森下
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K48/00 , A61P7/02 , A61P9/10 , A61P9/14 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a new medicinal composition for angiogenic therapy.SOLUTION: The present invention discloses the medicinal composition for the angiogenic therapy containing, as effective components, at least one kind selected from the group comprising substances having a vasodilation effect and/or a platelet aggregation restraining effect, and substances generating the substances, and a gene encoding an angiogenesis factor. an enhancement agent for an angiogenic effect by a gene of encoding the angiogenesis factor, containing, as the effective components, at least one kind selected from the group comprising the substances having the vasodilation effect and/or the platelet aggregation restraining effect, and the substances generating the substances, an angiogenic medicine containing a prostacyclin synthetase gene as an active component, the medicinal composition for the angiogenic therapy containing an ets-1 gene and other gene encoding the angiogenesis factor as effective components, an enhancement agent for the angiogenic effect by the other gene encoding the angiogenesis factor, containing the ets-1 gene as the effective component, and an angiogenic medicine containing the ets-1 gene as an effective component.
摘要翻译：要解决的问题：提供用于血管生成治疗的新药物组合物。解决方案：本发明公开了用于血管生成治疗的药物组合物，其含有选自包含具有血管舒张作用和/或血小板聚集抑制作用的物质的组中的至少一种作为有效成分，以及产生该物质的物质，以及编码血管生成因子的基因。包含编码血管生成因子的基因的血管生成作用的增强剂，其含有选自包含具有血管舒张作用和/或血小板聚集抑制作用的物质的组中的至少一种作为有效成分，以及所述物质生成含有前列环素合成酶基因作为活性成分的血管生成药物，含有ets-1基因的血管发生疗法的药物组合物和编码血管生成因子的其他基因作为有效成分，作为血管生成作用的增效剂含有ets-1基因作为有效成分的编码血管生成因子的其他基因，以及含有ets-1基因作为有效成分的血管生成药。版权所有（C）2012，JPO＆INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式